GNP Eye Drops Maximum Redness Relief (PLD)
- Manufacturer
- AmerisourceBergen | K.C. Pharmaceuticals, Inc.
- Effective date
- 2023-12-23
- Label type
- HUMAN OTC DRUG LABEL
- Version
- 3
- Source
- full-release
- Hydrated at
- 2026-06-01 00:05:35
Label at a glance#
Contacts and useful links#
Label contents#
Full prescribing information#
OTC - ACTIVE INGREDIENT SECTION
Active ingredients
Glycerin.....0.5%
Naphazoline HCl...0.03%
OTC - PURPOSE SECTION
Purpose
Glycerin.....Lubricant
Naphazoline HCl...Redness reliever
INDICATIONS & USAGE SECTION
Uses
- for the relief of redness of the eye due to minor eye irritations
- for the temporary relief of burning and irritation due to dryness of the eye
- for use as a protectant against further irritation or dryness of the eye
WARNINGS SECTION
Warnings
For external use only
OTC - DO NOT USE SECTION
Do not use if solution changes color or becomes cloudy
OTC - ASK DOCTOR SECTION
Ask a doctor before use if you have narrow angle glaucoma
OTC - WHEN USING SECTION
When using this product
- to avoid contamination, do not touch tip of container to any surface
- replace cap after using
- overuse may producte increased redness of the eye
- pupils may become enlarged temporarily
OTC - STOP USE SECTION
Stop use and ask a doctor if
- you experience eye pain
- you experience changes in vision
- you experience continued redness or irritation of the eye
- the condition worsens or persists for more than 72 hours
OTC - KEEP OUT OF REACH OF CHILDREN SECTION
Keep out of reach of children. If swallowed, get medical help or contact a Poison Control Center (1-800-222-1222) right away.
DOSAGE & ADMINISTRATION SECTION
Directions
Instill 1 to 2 drops in the affected eye(s) up to 4 times daily.
OTHER SAFETY INFORMATION
Other information
- store at room temperature
- remove contact lenses before using
INACTIVE INGREDIENT SECTION
Inactive ingredients
benzalkonium chloride, boric acid, edetate disodium, purified water, sodium borate
OTC - QUESTIONS SECTION
Questions or comments?
Call 1-866-627-4278
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL
DailyMed Product Concepts#
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| 777d68c6-a5ab-e06c-d314-677b0b9af0c8 | Product name | 2 | 20240508 |
| e18001c8-33ae-5f66-9cdc-a39724bd4573 | Product name | 1 | 20140508 |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 46122-603-05 | GNP EyeDrops Maximum Redness Relief | 1 in 1 CARTON | SOLUTION | 1 | 3 | |
| 46122-603-05 | GNP EyeDrops Maximum Redness Relief | 15 mL in 1 BOTTLE, DROPPER | SOLUTION | 15 | 3 |
DailyMed Dashboard NDC Coverage#
DailyMed Billing Units#
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 46122-603-05 | ML - Milliliter | 46122-603 | f6ac5a55-6337-4e53-b8d3-bee1ad66244e | 1 | 2023-02-06 |
Products#
Every source-derived product name is available through these pages.
- GNP EyeDrops Maximum Redness Relief
- glycerin, naphazoline HCl
- NAPHAZOLINE HYDROCHLORIDE
- NAPHAZOLINE
- GLYCERIN
- BORIC ACID
- WATER
- BENZALKONIUM CHLORIDE
- EDETATE DISODIUM
- EDETIC ACID
- SODIUM BORATE
NDC Codes#
| Product NDC | Package NDC |
|---|---|
| 46122-603 | 46122-603-05 |
Ingredients#
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| NAPHAZOLINE HYDROCHLORIDE | MZ1131787D | ACTIB |
| GLYCERIN | PDC6A3C0OX | ACTIB |
| BORIC ACID | R57ZHV85D4 | IACT |
| WATER | 059QF0KO0R | IACT |
| BENZALKONIUM CHLORIDE | F5UM2KM3W7 | IACT |
| EDETATE DISODIUM | 7FLD91C86K | IACT |
| SODIUM BORATE | 91MBZ8H3QO | IACT |
Source Document#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 53539606-c89e-cb5f-e063-6394a90a35a9 | 9b594424-08ad-c006-e053-2a95a90af91e | 2026-06-03 | Warnings | 9b594424-08ad-c006-e053-2a95a90af91e |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.
